The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 02, 2021

Filed:

Mar. 26, 2013
Applicants:

Golden Biotechnology Corporation, New Jersey, NJ (US);

Sheng-yung Liu, New Taipei, TW;

Wu-che Wen, New Taipei, TW;

Chih-ming Chen, New Taipei, TW;

Inventors:

Sheng-Yung Liu, New Taipei, TW;

Wu-Che Wen, New Taipei, TW;

Chih-Ming Chen, New Taipei, TW;

Assignee:

Golden Biotechnology Corporation, Jersey City, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/122 (2006.01); A61P 3/10 (2006.01); A61K 36/07 (2006.01); A61K 31/133 (2006.01); A61P 9/10 (2006.01); C07C 49/753 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/122 (2013.01); A61K 31/133 (2013.01); A61K 36/07 (2013.01); A61P 9/10 (2018.01); C07C 49/753 (2013.01); A61K 9/0014 (2013.01); A61K 9/0031 (2013.01); A61K 9/0048 (2013.01); A61K 9/0056 (2013.01); A61K 9/0078 (2013.01); A61K 9/4858 (2013.01);
Abstract

The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.


Find Patent Forward Citations

Loading…